Founded in 2020, Lerna Biopharma is a preclinical-stage biopharmaceutical company developing innovative oligonucleotide therapeutics for liver diseases and ophthalmic disorders, with operations in Singapore, China and USA.
Using proprietary platforms backed by novel biology and chemistry insights, Lerna aims to improve quality of life for millions of patients worldwide through creating highly specific, stable and potent nucleic acid-based medicines for the treatment of a broad range of diseases.
In December 2021, Lerna successfully closed an over-subscribed US$19.2 million pre-Series A funding round led by BioTrack Capital, with participation from Hyfinity Investments, Legendstar Capital and other renowned investors.
Company Details
- Employees
- 4
- Founded
- 2020
- Address
- 1 Biopolis Drive, Aminos #05-01,singapore
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.lernabio.com
- HQ
- Singapore
Lerna Biopharma Questions
Lerna Biopharma's website is http://www.lernabio.com
Lerna Biopharma's LinkedIn profile is https://sg.linkedin.com/company/lerna-biopharma
Lerna Biopharma has
4 employees.
View email and phone details for 4
employees at Lerna Biopharma.
Lerna Biopharma's industry is
Biotechnology Research
Lerna Biopharma's top competitors are
Hummingbird Bioscience,
Singzyme,
Nuevocor,
Carcell Biopharma,
Carmine Therapeutics,
Clavystbio,
Evx Ventures,
Tikva Allocell Pte Ltd,
Axcynsis Therapeutics,
Mirxes.
Lerna Biopharma's categories are Biotechnology Research
Lerna Biopharma's founding year is 2020
